Toggle Main Menu Toggle Search

Open Access padlockePrints

Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice

Lookup NU author(s): Professor Hermann Josef Vormoor

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Development of distant metastasis is the major reason for cancer-related deaths worldwide. Adjuvant therapy approaches after local therapies are most effective when specific targets are inhibited. Recently, we identified S100P overexpression as a strong predictor for metastasis development in early-stage non-small cell lung cancer (NSCLC) patients. Here, we show that S100P overexpression increased angiogenesis in and metastasis formation from s.c. xenotransplants of NSCLC cells. Plasmid-derived short hairpin RNAs (shRNA) were developed as specific adjuvant therapy. I.v. injected shRNA against S100P significantly decreased S100P protein expression in xenograft tumors and inhibited tumor angiogenesis in vivo. Metastasis formation 8 weeks after primary tumor resection was significantly reduced. Lung metastases developed in 31% of mice treated with S100P-targeting shRNAs compared with 64% in control shRNA-treated mice (P < 0.05). These findings suggest that RNA interference-based therapy approaches can be highly effective in the adjuvant setting. ©2008 American Association for Cancer Research.


Publication metadata

Author(s): Bulk, E., Hascher, A., Liersch, R., Mesters, R.M., Diederichs, S., Sargin, B., Gerke, V., Hotfilder, M., Vormoor, H.J., Berdel, W.E., Serve, H., Müller-Tidow, C.

Publication type: Article

Publication status: Published

Journal: Cancer Research

Year: 2008

Volume: 68

Issue: 6

Pages: 1896-1904

Print publication date: 15/03/2008

ISSN (print): 0008-5472

ISSN (electronic): 1538-7445

URL: http://dx.doi.org/10.1158/0008-5472.CAN-07-2390

DOI: 10.1158/0008-5472.CAN-07-2390

PubMed id: 18339871


Altmetrics

Altmetrics provided by Altmetric


Share